Turnstone Biologics Investor Relations Material

Turnstone Biologics Corp is a clinical-stage biotechnology company engaged in developing innovative therapies for patients with solid tumors. Their work is centered around the development of tumor infiltrating lymphocytes (TIL) therapies, with a specific focus on selecting and expanding potent tumor-reactive T cells to address the limitations of bulk TILs. Their pipeline includes TIDAL-01 and TIDAL-02, with TIDAL-01 being their lead selected TIL product candidate. This candidate utilizes an unbiased identification and functional screening process to isolate and expand a broad range of tumor-reactive TILs from a patient's tumor. The company is headquartered in La Jolla, California, and its shares are listed on the Nasdaq under the symbol TSBX.